Tag: luminalA

Articles

• Breast cancer types

News

09/17/17

KI-67 linked to survival in women with luminal breast cancer

01/20/13

Some BC types have up to 11% locoregional recurrence after mastectomy

11/05/11

Luminal BC prognosis can vary based on other tumor characteristics

08/01/11

BC subtype influences prognosis after neoadjuvant chemotherapy

Studies

• Metabolic syndrome and risks of breast cancer outcomes for luminal, triple-negative, and HER2-overexpressing subtypes Cite
  Loroña NC, Othus M, Malone KE, Linden HM, Tang MC, Li CI. Metabolic syndrome and risks of breast cancer outcomes for luminal, triple-negative, and HER2-overexpressing subtypes. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2024; 10.1158/1055-9965.epi-24-1167
• Increasing rates of early-onset Luminal A breast cancers correlate with binge drinking patterns Cite
  Chen J, Kehm R, Yang W, Terry MB. Increasing rates of early-onset Luminal A breast cancers correlate with binge drinking patterns. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01894-7
• Characterization of Molecular Subtypes of Rat Mammary Cancer and Their Association With Environmental Exposures Cite
  NISHIMURA Y, IIZUKA D, TAKABATAKE M, DAINO K, NISHIMURA M, MORIOKA T, et al. Characterization of Molecular Subtypes of Rat Mammary Cancer and Their Association With Environmental Exposures. Anticancer Research. Anticancer Research USA Inc.; 2024; 44:4261-4272 10.21873/anticanres.17256
• 21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer Cite
  Wang R, Liu H, Guo L, Yu D, Wu S. 21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01636-9
• Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: A prospective cohort study Cite
  Busund MK, Ursin G, Lund E, Chen SLF, Rylander C. Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: A prospective cohort study. Springer Science and Business Media LLC; 2024; 10.21203/rs.3.rs-4912071/v1
• Racial/ethnic differences in the clinical presentation and survival of breast cancer by subtype Cite
  Nhim V, Bencomo-Alvarez AE, Alvarado L, Kilcoyne M, Gonzalez-Henry MA, Olivas IM, et al. Racial/ethnic differences in the clinical presentation and survival of breast cancer by subtype. Frontiers in Oncology. Frontiers Media SA; 2024; 14 10.3389/fonc.2024.1443399
• Cheese intake, probiotics and breast cancer: A Mendelian randomization analysis Cite
  Jia Y, Feng C, Sun S, Li C, Li J, Yao P, et al. Cheese intake, probiotics and breast cancer: A Mendelian randomization analysis. Journal of Functional Foods. Elsevier BV; 2024; 119:106352 10.1016/j.jff.2024.106352
• Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study Cite
  John EM, Koo J, Phipps AI, Longacre TA, Kurian AW, Ingles SA, et al. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01834-5
• Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway Cite
  Støer NC, Vangen S, Singh D, Fortner RT, Hofvind S, Ursin G, et al. Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. British Journal of Cancer. Springer Science and Business Media LLC; 2024; 10.1038/s41416-024-02590-1
• An analysis of the association between breast density and body mass index with breast cancer molecular subtypes in early breast cancer: data from a Spanish population Cite
  Calvo I, González-Rodríguez M, Neria F, Gallegos I, García-Sánchez L, Sánchez-Gómez R, et al. An analysis of the association between breast density and body mass index with breast cancer molecular subtypes in early breast cancer: data from a Spanish population. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2024; 10.1007/s12094-024-03469-6
• Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer Cite
  Li S, Hammarlund JA, Wu G, Lian J, Howell SJ, Clarke RB, et al. Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2024; 121 10.1073/pnas.2311854121
• Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study Cite
  Hung S, Yang H, Lee M, Liu D, Chen L, Chew C, et al. Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01747-9
• Ketogenic diet does not promote triple-negative and luminal mammary tumor growth and metastasis in experimental mice Cite
  Grube M, Dimmler A, Schmaus A, Saup R, Wagner T, Garvalov BK, et al. Ketogenic diet does not promote triple-negative and luminal mammary tumor growth and metastasis in experimental mice. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2023; 10.1007/s10585-023-10249-z
• Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study Cite
  Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, et al. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study. European Journal of Cancer. Elsevier BV; 2023; 195:113397 10.1016/j.ejca.2023.113397
• Alcohol, smoking, and risks of breast cancer recurrence and mortality among women with luminal, triple-negative, and HER2-overexpressing breast cancer Cite
  Loroña NC, Othus M, Malone KE, Linden HM, Tang MC, Li CI. Alcohol, smoking, and risks of breast cancer recurrence and mortality among women with luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2023; 10.1158/1055-9965.epi-23-1081
• AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer Cite
  Lu W, Lashen AG, Wahab N, Miligy IM, Jahanifar M, Toss M, et al. AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer. The Journal of Pathology: Clinical Research. Wiley; 2023; 10.1002/cjp2.346
• Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer Cite
  da Silva FC, Brandão DC, Ferreira EA, Siqueira RP, Ferreira HSV, Da Silva Filho AA, et al. Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer. Pharmaceuticals. MDPI AG; 2023; 16:1466 10.3390/ph16101466
• The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer Cite
  Bimonte VM, Catanzaro G, Po A, Trocchianesi S, Besharat ZM, Spinello Z, et al. The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3359720/v1
• Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial Cite
  Nielsen TO, Leung SCY, Riaz N, Mulligan AM, Kos Z, Bane A, et al. Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial. Histopathology. Wiley; 2023; 10.1111/his.15032
• Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry Cite
  Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, et al. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07022-x
• Prognostic factors in Luminal B-like HER2-negative breast cancer tumors Cite
  Castellarnau-Visús M, Soveral I, Regueiro Espín P, Pineros Manzano J, Del Río M. Prognostic factors in Luminal B-like HER2-negative breast cancer tumors. Surgical Oncology. Elsevier BV; 2023;:101968 10.1016/j.suronc.2023.101968
• Ki 67 Cut-off Level & mPEPI Score: Any Predictive Role for Neoadjuvant ‘Chemotherapy’ Efficacy in Locally Advanced HER2 Negative Luminal-like Breast Cancer? Cite
  Dogan M, Karacin C, Kaman O, Bulut ZM, Kiziltan G, Oksuzoglu B, et al. Ki 67 Cut-off Level & mPEPI Score: Any Predictive Role for Neoadjuvant ‘Chemotherapy’ Efficacy in Locally Advanced HER2 Negative Luminal-like Breast Cancer?. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2756296/v1
• The Effect of Cholesterol in MCF7 Human Breast Cancer Cells Cite
  Albi E, Mandarano M, Cataldi S, Ceccarini MR, Fiorani F, Beccari T, et al. The Effect of Cholesterol in MCF7 Human Breast Cancer Cells. International Journal of Molecular Sciences. MDPI AG; 2023; 24:5935 10.3390/ijms24065935
• The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up Cite
  Lashen AG, Toss MS, Mongan NP, Green AR, Rakha EA. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up. Cancer. Wiley; 2023; 10.1002/cncr.34655
• Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden Cite
  Lindman H, Wiklund F, Andersen KK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden. BMC Cancer. Springer Science and Business Media LLC; 2022; 22 10.1186/s12885-022-10098-1
• Postmenopausal overweight and breast cancer risk; results from the KARMA cohort Cite
  Klintman M, Rosendahl AH, Randeris B, Eriksson M, Czene K, Hall P, et al. Postmenopausal overweight and breast cancer risk; results from the KARMA cohort. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06664-7
• Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women's Health History Study Cite
  Ihenacho U, Hamilton AS, Mack WJ, Wu AH, Unger JB, Pathak DR, et al. Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women's Health History Study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06675-4
• The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute Cite
  Gamrani S, Boukansa S, Benbrahim Z, Mellas N, Fdili Alaoui F, Melhouf MA, et al. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER−/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute. The Breast Journal. Hindawi Limited; 2022; 2022:1-9 10.1155/2022/9238804
• Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival Cite
  Chen Y, Zhang T, Liu Y, Zheng J, Lin W, Chen Y, et al. Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival. Genetica. Springer Science and Business Media LLC; 2022; 10.1007/s10709-022-00157-7
• The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study Cite
  Hayati Z, Montazeri V, Shivappa N, Hebert JR, Pirouzpanah S. The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study. Cancer. Wiley; 2022; 10.1002/cncr.34183
• Abstract P3-18-03: Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC) Cite
  Wang K, Duinmeijer A, Matikas A, Altena R, Johansson H, Fredholm H, et al. Abstract P3-18-03: Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC). Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-18-03-P3-18-03 10.1158/1538-7445.sabcs21-p3-18-03
• Adherence to Endocrine Therapy Predicts Short-Term Clinical Outcomes for Postmenopausal Women With Luminal B but Not Luminal A Breast Cancer Cite
  Fahey M, Mills M, Liveringhouse C, Ronica N, Diaz R. Adherence to Endocrine Therapy Predicts Short-Term Clinical Outcomes for Postmenopausal Women With Luminal B but Not Luminal A Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2021; 111:e206 10.1016/j.ijrobp.2021.07.730
• Parity and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis Cite
  Li C, Fan Z, Lin X, Cao M, Song F, Song F. Parity and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis. Cancer Epidemiology. Elsevier BV; 2021; 75:102050 10.1016/j.canep.2021.102050
• Reproductive history differs by molecular subtypes of breast cancer among women aged ≤50 years in Scotland in 2009-16: A population-based retrospective cohort study Cite
  Chitkara A, Mesa-Eguiagaray I, Wild SH, Hall PS, Cameron D, Figueroa J. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤50 years in Scotland in 2009-16: A population-based retrospective cohort study. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-940729/v1
• Intrinsic Subtypes and Androgen Receptor Gene Expression in Primary Breast Cancer. A Meta-Analysis Cite
  Cruz-Tapias P, Rubiano W, Rondón-Lagos M, Villegas V, Rangel N. Intrinsic Subtypes and Androgen Receptor Gene Expression in Primary Breast Cancer. A Meta-Analysis. Biology. MDPI AG; 2021; 10:834 10.3390/biology10090834
• Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression Cite
  Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, et al. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis & Therapy. Springer Science and Business Media LLC; 2021; 10.1007/s40291-021-00525-7
• Potential Diagnostic Significance of Salivary Copper Determination in Breast Cancer Patients: A Pilot Study Cite
  Bel’skaya LV, Sarf EA, Shalygin SP, Postnova TV, Kosenok VK. Potential Diagnostic Significance of Salivary Copper Determination in Breast Cancer Patients: A Pilot Study. Biological Trace Element Research. Springer Science and Business Media LLC; 2021; 10.1007/s12011-021-02710-5
• Low Levels of Omega-3 Long-Chain Polyunsaturated Fatty Acids Are Associated with Bone Metastasis Formation in Premenopausal Women with Breast Cancer: A Retrospective Study Cite
  Goupille C, Frank PG, Arbion F, Jourdan M, Guimaraes C, Pinault M, et al. Low Levels of Omega-3 Long-Chain Polyunsaturated Fatty Acids Are Associated with Bone Metastasis Formation in Premenopausal Women with Breast Cancer: A Retrospective Study. Nutrients. MDPI AG; 2020; 12:3832 10.3390/nu12123832
• BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients Cite
  Incorvaia L, Fanale D, Bono M, Calò V, Fiorino A, Brando C, et al. BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients. Therapeutic Advances in Medical Oncology. SAGE Publications; 2020; 12:175883592097532 10.1177/1758835920975326
• The impact of selected risk factors among breast cancer molecular subtypes: a case-only study Cite
  Pizzato M, Carioli G, Rosso S, Zanetti R, La Vecchia C. The impact of selected risk factors among breast cancer molecular subtypes: a case-only study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:213-220 10.1007/s10549-020-05820-1
• Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database Cite
  Nahleh ZA, Elimimian EB, Elson LC, Hobbs B, Wei W, Blake CN. Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2020; 14:117822342094569 10.1177/1178223420945694
• Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy Cite
  Hamy A, Darrigues L, Laas E, De Croze D, Topciu L, Lam G, et al. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0234191 10.1371/journal.pone.0234191
• Abstract P6-15-05: Demographics and survival in metastatic inflammatory breast cancer. SEER data analysis Cite
  Anusim N, Ionescu F, Khoury J, Konde A, Jaiyesimi I. Abstract P6-15-05: Demographics and survival in metastatic inflammatory breast cancer. SEER data analysis. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p6-15-05
• The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes Cite
  Min W, Wang B, Guo A, Mao G, Zhao Y, Zhang S, et al. The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes. World Journal of Oncology. Elmer Press, Inc.; 2020; 11:23-32 10.14740/wjon1242
• Body mass index and risk of breast cancer molecular subtypes in Korean women: a case–control study Cite
  Jeong SH, An Y, Ahn C, Park B, Lee MH, Noh D, et al. Body mass index and risk of breast cancer molecular subtypes in Korean women: a case–control study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:459-470 10.1007/s10549-019-05451-1
• Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics Cite
  Blair CK, Wiggins CL, Nibbe AM, Storlie CB, Prossnitz ER, Royce M, et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. npj Breast Cancer. Springer Science and Business Media LLC; 2019; 5 10.1038/s41523-019-0128-4
• Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer Cite
  Yu NY, Iftimi A, Yau C, Tobin NP, van ’t Veer L, Hoadley KA, et al. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2019; 5:1304 10.1001/jamaoncol.2019.1856
• Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer Cite
  Lorona NC, Cook LS, Tang MC, Hill DA, Wiggins CL, Li CI. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer. Hormones and Cancer. Springer Science and Business Media LLC; 2019; 10:71-76 10.1007/s12672-019-00362-5
• A high-risk luminal A dominant breast cancer subtype with increased mobility Cite
  Guo L, Chen G, Zhang W, Zhou L, Xiao T, Di X, et al. A high-risk luminal A dominant breast cancer subtype with increased mobility. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:459-472 10.1007/s10549-019-05135-w
• Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study Cite
  Williams LA, Casbas-Hernandez P, Nichols HB, Tse CK, Allott EH, Carey LA, et al. Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. PLOS ONE. Public Library of Science (PLoS); 2019; 14:e0211488 10.1371/journal.pone.0211488
• Soy Foods Might Weaken the Sensitivity of Tamoxifen in Premenopausal Patients With Lumina A Subtype of Breast Cancer Cite
  Deng K, Mo S, Liu X, Chen J, Zhang Q, Chen X, et al. Soy Foods Might Weaken the Sensitivity of Tamoxifen in Premenopausal Patients With Lumina A Subtype of Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2018; 19:e337-e342 10.1016/j.clbc.2018.12.003
• Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study Cite
  Liu Z, Sahli Z, Wang Y, Wolff AC, Cope LM, Umbricht CB. Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 172:689-702 10.1007/s10549-018-4950-4
• Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy Cite
  Goto W, Kashiwagi S, Takada K, Asano Y, Takahashi K, Fujita H, et al. Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. Journal of Translational Medicine. Springer Science and Business Media LLC; 2018; 16 10.1186/s12967-018-1679-0
• Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study Cite
  van Maaren MC, de Munck L, Strobbe LJ, Sonke GS, Westenend PJ, Smidt ML, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. International Journal of Cancer. Wiley; 2018; 144:263-272 10.1002/ijc.31914
• Number of Risky Lifestyle Behaviors and Breast Cancer Risk Cite
  Ellingjord-Dale M, Vos L, Vik Hjerkind K, Hjartåker A, Russnes HG, Tretli S, et al. Number of Risky Lifestyle Behaviors and Breast Cancer Risk. JNCI Cancer Spectrum. Oxford University Press (OUP); 2018; 2 10.1093/jncics/pky030
• Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow‐up Cite
  Farvid MS, Chen WY, Rosner BA, Tamimi RM, Willett WC, Eliassen AH. Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow‐up. International Journal of Cancer. Wiley; 2018; 144:1496-1510 10.1002/ijc.31653
• Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy Cite
  Cabrera‐Galeana P, Muñoz‐Montaño W, Lara‐Medina F, Alvarado‐Miranda A, Pérez‐Sánchez V, Villarreal‐Garza C, et al. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. The Oncologist. Wiley; 2018; 23:670-678 10.1634/theoncologist.2017-0396
• Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial. Cite
  Lindström L, Yu N, Iftimi A, Yau C, van 't Veer L, Nordenskjöld B, et al. Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:541-541 10.1200/jco.2018.36.15_suppl.541
• Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy Cite
  Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:559-567 10.1007/s10549-018-4801-3
• Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences Cite
  Tayyari F, Gowda GN, Olopade OF, Berg R, Yang HH, Lee MP, et al. Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. Oncotarget. Impact Journals, LLC; 2018; 9:11677-11690 10.18632/oncotarget.24433
• Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients Cite
  Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu F, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:35-43 10.1007/s10549-018-4730-1
• Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database Cite
  Hwang K, Kim E, Jung SH, Lee ES, Kim SI, Lee S, et al. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 169:311-322 10.1007/s10549-018-4681-6
• The prognostic role of tumor size in early breast cancer in the era of molecular biology Cite
  Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, et al. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0189127 10.1371/journal.pone.0189127
• Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes Cite
  Sánchez-Muñoz A, Vicioso L, Santonja A, Álvarez M, Plata-Fernández Y, Miramón J, et al. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. Modern Pathology. Springer Science and Business Media LLC; 2017; 31:299-306 10.1038/modpathol.2017.129
• The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer Cite
  Lian W, Fu F, Lin Y, Lu M, Chen B, Yang P, et al. The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer. Scientific Reports. Springer Science and Business Media LLC; 2017; 7 10.1038/s41598-017-10414-x
• Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis Cite
  Gallardo A, Garcia-Valdecasas B, Murata P, Teran R, Lopez L, Barnadas A, et al. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:31-37 10.1007/s10549-017-4486-z
• Lineage-Restricted Mammary Stem Cells Sustain the Development, Homeostasis, and Regeneration of the Estrogen Receptor Positive Lineage Cite
  Van Keymeulen A, Fioramonti M, Centonze A, Bouvencourt G, Achouri Y, Blanpain C. Lineage-Restricted Mammary Stem Cells Sustain the Development, Homeostasis, and Regeneration of the Estrogen Receptor Positive Lineage. Cell Reports. Elsevier BV; 2017; 20:1525-1532 10.1016/j.celrep.2017.07.066
• A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer Cite
  Borges US, Costa-Silva DR, da Silva-Sampaio JP, Escórcio-Dourado CS, Conde AM, Campelo V, et al. A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer. Medical Oncology. Springer Science and Business Media LLC; 2017; 34 10.1007/s12032-017-1019-x
• Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231 Cite
  Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A. Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. Scientific Reports. Springer Science and Business Media LLC; 2017; 7 10.1038/s41598-017-07489-x
• Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study Cite
  Healey MA, Hirko KA, Beck AH, Collins LC, Schnitt SJ, Eliassen AH, et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 166:613-622 10.1007/s10549-017-4421-3
• Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype Cite
  McGuire A, Lowery AJ, Kell MR, Kerin MJ, Sweeney KJ. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:3124-3132 10.1245/s10434-017-6021-1
• The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy Cite
  Alabdulkareem H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, et al. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. Wiley; 2017; 24:148-153 10.1111/tbj.12853
• The Association of Mammographic Density and Molecular Breast Cancer Subtype Cite
  Edwards BL, Atkins KA, Stukenborg GJ, Novicoff WM, Larson KN, Cohn WF, et al. The Association of Mammographic Density and Molecular Breast Cancer Subtype. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 26:1487-1492 10.1158/1055-9965.epi-16-0881
• Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer Cite
  Hage AN, Capriccioso C, Brennan J, Heiden B, Zheutlin A, Sabel MS. Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer. Journal of Surgical Oncology. Wiley; 2017; 116:665-670 10.1002/jso.24721
• Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer Cite
  Cespedes Feliciano EM, Kwan ML, Kushi LH, Chen WY, Weltzien EK, Castillo AL, et al. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. Cancer. Wiley; 2017; 123:2535-2542 10.1002/cncr.30637
• The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment Cite
  Ayoub NM, Siddique AB, Ebrahim HY, Mohyeldin MM, El Sayed KA. The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. European Journal of Pharmacology. Elsevier BV; 2017; 810:100-111 10.1016/j.ejphar.2017.06.019
• Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells Cite
  Javan-Maasomi Z, Pilehvar-Soltanahmadi Y, Dadashpour M, Alipour S, Abolhasani S, Zarghami N. Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention. Asian Pacific Organization for Cancer Prevention; 2017; 18 10.22034/APJCP.2017.18.5.1283
• Breastfeeding Cite
  Giudici F, Scaggiante B, Scomersi S, Bortul M, Tonutti M, Zanconati F. Breastfeeding. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2017; 26:217-224 10.1097/cej.0000000000000220
• Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice Cite
  Lim YJ, Lee S, Choi N, Kwon J, Eom K, Kang E, et al. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:555-563 10.1007/s10549-017-4206-8
• Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index Cite
  Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Clinical Breast Cancer. Elsevier BV; 2017; 17:41-47 10.1016/j.clbc.2016.06.012
• Molecular Subtypes and Prognosis in Young Mexican Women With Breast Cancer Cite
  Villarreal-Garza C, Mohar A, Bargallo-Rocha JE, Lasa-Gonsebatt F, Reynoso-Noverón N, Matus-Santos J, et al. Molecular Subtypes and Prognosis in Young Mexican Women With Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2017; 17:e95-e102 10.1016/j.clbc.2016.11.007
• Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences Cite
  Valla M, Vatten LJ, Engstrøm MJ, Haugen OA, Akslen LA, Bjørngaard JH, et al. Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2016; 25:1625-1634 10.1158/1055-9965.epi-16-0427
• Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study Cite
  Diessner J, Wischnewsky M, Blettner M, Häusler S, Janni W, Kreienberg R, et al. Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0168730 10.1371/journal.pone.0168730
• Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy Cite
  Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 161:173-179 10.1007/s10549-016-4031-5
• Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology) Cite
  Kaplan MA, Arslan UY, Işıkdogan A, Dane F, Oksuzoglu B, Inanc M, et al. Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology). Breast Care. S. Karger AG; 2016; 11:248-252 10.1159/000448186
• Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes Cite
  Kim S, Chun M, Han S, Jung YS, Choi JH, Kang SY, et al. Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes. Cancer Research and Treatment. Korean Cancer Association; 2017; 49:484-493 10.4143/crt.2016.246
• Abstract 1759: The association between alcohol, physical activity and breast cancer subtypes in a nested case-control study from the Norwegian Breast Cancer Screening Program Cite
  Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Abstract 1759: The association between alcohol, physical activity and breast cancer subtypes in a nested case-control study from the Norwegian Breast Cancer Screening Program. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-1759
• Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study Cite
  Ma H, Xu X, Clague J, Lu Y, Togawa K, Wang SS, et al. Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0723-3
• Prognostic and predictive value of Ki-67 in triple-negative breast cancer Cite
  Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. Impact Journals, LLC; 2016; 7:31079-31087 10.18632/oncotarget.9075
• Active smoking and risk of Luminal and Basal-like breast cancer subtypes in the Carolina Breast Cancer Study Cite
  Butler EN, Tse C, Bell ME, Conway K, Olshan AF, Troester MA. Active smoking and risk of Luminal and Basal-like breast cancer subtypes in the Carolina Breast Cancer Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:775-786 10.1007/s10552-016-0754-1
• Prognostic impact of breast cancer subtypes in elderly patients Cite
  Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, et al. Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:91-99 10.1007/s10549-016-3787-y
• Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study Cite
  Agresti R, Meneghini E, Baili P, Minicozzi P, Turco A, Cavallo I, et al. Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:179-189 10.1007/s10549-016-3802-3
• Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma Cite
  Adachi Y, Ishiguro J, Kotani H, Hisada T, Ichikawa M, Gondo N, et al. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2275-4
• Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database Cite
  Tseng YD, Uno H, Hughes ME, Niland JC, Wong Y, Theriault R, et al. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2015; 93:622-630 10.1016/j.ijrobp.2015.07.006
• The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy? Cite
  Sun Y, Liu X, Cui S, Li L, Tian P, Liu S, et al. The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?. Tumor Biology. Springer Science and Business Media LLC; 2016; 37:9555-9563 10.1007/s13277-016-4844-1
• Alcohol and breast cancer tumor subtypes in a Spanish Cohort Cite
  Gago-Dominguez M, Castelao JE, Gude F, Fernandez MP, Aguado-Barrera ME, Ponte SM, et al. Alcohol and breast cancer tumor subtypes in a Spanish Cohort. SpringerPlus. Springer Science and Business Media LLC; 2016; 5 10.1186/s40064-015-1630-2
• Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy Cite
  Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine. Springer Science and Business Media LLC; 2015; 13 10.1186/s12916-015-0540-z
• Long-term survival and stage I breast cancer subtypes Cite
  Cheng SH, Yu B, Horng C, Tsai SY, Chen C, Chu N, et al. Long-term survival and stage I breast cancer subtypes. Journal of Cancer Research and Practice. Medknow; 2016; 3:1-8 10.1016/j.jcrpr.2015.10.005
• High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer Cite
  Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2015; 15:204-211 10.1016/j.clbc.2014.12.007
• Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival Cite
  Lee SK, Bae SY, Lee JH, Lee H, Yi H, Kil WH, et al. Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0124658 10.1371/journal.pone.0124658
• Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy Cite
  Liu F, Shi W, Done SJ, Miller N, Pintilie M, Voduc D, et al. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2035-2040 10.1200/jco.2014.57.7999
• Abstract P2-04-05: Modeling luminal breast cancer heterogeneity: Combination therapies to suppress hormone receptor-negative subpopulations among receptor-positive ones Cite
  Scaling AL, Knox AJ, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA, et al. Abstract P2-04-05: Modeling luminal breast cancer heterogeneity: Combination therapies to suppress hormone receptor-negative subpopulations among receptor-positive ones. Poster Session Abstracts. American Association for Cancer Research; 2015; 10.1158/1538-7445.sabcs14-p2-04-05
• Breastfeeding, PAM50 Tumor Subtype, and Breast Cancer Prognosis and Survival Cite
  Kwan ML, Bernard PS, Kroenke CH, Factor RE, Habel LA, Weltzien EK, et al. Breastfeeding, PAM50 Tumor Subtype, and Breast Cancer Prognosis and Survival. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107 10.1093/jnci/djv087
• Breast Cancer Subtypes Predispose the Site of Distant Metastases Cite
  Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, et al. Breast Cancer Subtypes Predispose the Site of Distant Metastases. American Journal of Clinical Pathology. Oxford University Press (OUP); 2015; 143:471-478 10.1309/ajcpyo5fsv3upexs
• Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Cite
  Sheridan W, Scott T, Caroline S, Yvonne Z, Vanessa B, David V, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 147:617-629 10.1007/s10549-014-3125-1
• The prognostic value of lymph node status among breast cancer subtypes Cite
  Liao G, Chou Y, Hsu H, Dai M, Yu J. The prognostic value of lymph node status among breast cancer subtypes. The American Journal of Surgery. Elsevier BV; 2015; 209:717-724 10.1016/j.amjsurg.2014.05.029
• Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer Cite
  Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2014; 14 10.1186/1471-2407-14-550
• Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort – Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake Cite
  Seibold P, Vrieling A, Heinz J, Obi N, Sinn H, Flesch-Janys D, et al. Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort – Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake. Cancer Epidemiology. Elsevier BV; 2014; 38:419-426 10.1016/j.canep.2014.05.006
• Which threshold for ER positivity? a retrospective study based on 9639 patients Cite
  Yi M, Huo L, Koenig K, Mittendorf E, Meric-Bernstam F, Kuerer H, et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. Annals of Oncology. Elsevier BV; 2014; 25:1004-1011 10.1093/annonc/mdu053
• Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial Cite
  Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Annals of Oncology. Elsevier BV; 2014; 25:1128-1136 10.1093/annonc/mdu118
• Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer Cite
  Li H, Chen K, Su F, Song E, Gong C. Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer. Journal of Surgical Research. Elsevier BV; 2014; 189:48-56 10.1016/j.jss.2014.02.048
• Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss Cite
  Braun L, Mietzsch F, Seibold P, Schneeweiss A, Schirmacher P, Chang-Claude J, et al. Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss. Modern Pathology. Springer Science and Business Media LLC; 2013; 26:1161-1171 10.1038/modpathol.2013.60
• Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction Cite
  Kneubil M, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, et al. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2013; 39:260-265 10.1016/j.ejso.2012.12.004
• Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties Cite
  Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, LaBarbera DV, et al. Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties. Hormones and Cancer. Springer Science and Business Media LLC; 2012; 4:36-49 10.1007/s12672-012-0127-5
• Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab Cite
  Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer. Springer Science and Business Media LLC; 2012; 21:563-570 10.1007/s12282-012-0424-4
• Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome Cite
  Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, et al. Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. Clinical Breast Cancer. Elsevier BV; 2013; 13:31-39 10.1016/j.clbc.2012.09.002
• Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype Cite
  Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 136:153-160 10.1007/s10549-012-2243-x
• Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology) Cite
  Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumussoy O, Yildiz R, et al. Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology). Oncology. S. Karger AG; 2012; 83:141-150 10.1159/000338782
• Tumour characteristics among women with very low-risk breast cancer Cite
  Narod SA, Valentini A, Nofech-Mozes S, Sun P, Hanna W. Tumour characteristics among women with very low-risk breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:1241-1246 10.1007/s10549-012-2065-x
• Luminal breast cancer metastasis is dependent on estrogen signaling Cite
  Ganapathy V, Banach-Petrosky W, Xie W, Kareddula A, Nienhuis H, Miles G, et al. Luminal breast cancer metastasis is dependent on estrogen signaling. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2012; 29:493-509 10.1007/s10585-012-9466-4
• Invasive lobular breast cancer: subtypes and outcome Cite
  Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 133:713-723 10.1007/s10549-012-2002-z
• Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype Cite
  Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 133:831-841 10.1007/s10549-011-1891-6
• Outcome of special types of luminal breast cancer Cite
  Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua M, Luini A, Veronesi P, et al. Outcome of special types of luminal breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:1428-1436 10.1093/annonc/mdr461
• Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer Cite
  Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, et al. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Medical Oncology. Springer Science and Business Media LLC; 2011; 29:1536-1542 10.1007/s12032-011-0082-y
• Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study Cite
  Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2011; 13 10.1186/bcr2944
• Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy Cite
  Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, et al. Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:3885-3891 10.1200/jco.2011.36.1105
• Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy. Cite
  Takita C, Reis IM, Miao F, LaFave KE, Gunaseelan V, Hurley J, et al. Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:112-112 10.1200/jco.2011.29.27_suppl.112
• Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer Cite
  Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, et al. Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer. Oncology. S. Karger AG; 2011; 80:341-349 10.1159/000330203
• Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer Cite
  Kim HJ, Lee YM, Ko BS, Lee JW, Yu JH, Son BH, et al. Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2010; 18:1830-1836 10.1245/s10434-010-1465-6
• Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype Cite
  Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes & Control. Springer Science and Business Media LLC; 2011; 22:965-975 10.1007/s10552-011-9769-9
• Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes Cite
  Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 127:713-720 10.1007/s10549-011-1465-7
• A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative Cite
  Thakkar JP, Mehta DG. A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative. The Oncologist. Wiley; 2011; 16:276-285 10.1634/theoncologist.2010-0302
• Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study Cite
  O'Brien KM, Cole SR, Tse C, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. Clinical Cancer Research. American Association for Cancer Research (AACR); 2010; 16:6100-6110 10.1158/1078-0432.ccr-10-1533
• Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study Cite
  Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, et al. Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study. Cancer Research. American Association for Cancer Research (AACR); 2010; 70:575-587 10.1158/0008-5472.can-09-3460
• Presenting Features of Breast Cancer Differ by Molecular Subtype Cite
  Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, et al. Presenting Features of Breast Cancer Differ by Molecular Subtype. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2009; 16:2705-2710 10.1245/s10434-009-0606-2
• ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies Cite
  Finn RS, Dering J, Ginther C, Press M, Forbes J, Mackey J, et al. ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2006; 24:514-514 10.1200/jco.2006.24.18_suppl.514
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer Cite
  Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2009; 101:736-750 10.1093/jnci/djp082